Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

Core Insights - Apyx Medical Corporation reported preliminary revenue results for Q4 and full year 2024, indicating a strong performance in the Advanced Energy segment with over 25% sales growth quarter-over-quarter [2][4] - The company anticipates launching the AYON™ Body Contouring System in the second half of 2025, pending FDA clearance, which is expected to enhance its position in the surgical aesthetics market [4] Preliminary Fourth Quarter 2024 Revenue Summary - Total revenue is expected to be in the range of approximately $14.1 to$ 14.3 million, representing a decrease of 4% to 3% year-over-year [6] - Advanced Energy revenue is expected to be in the range of approximately $12.0 to$ 12.2 million, which is relatively flat year-over-year [6] - OEM revenue is expected to be approximately $2.1 million, representing a decrease of 17% year-over-year [6] Preliminary Full Year 2024 Revenue Summary - Total revenue is expected to be in the range of approximately$ 48.0 to $48.2 million, representing a decrease of 8% year-over-year [6] - Advanced Energy revenue is expected to be in the range of approximately$ 38.5 to $38.7 million, representing a decrease of 11% year-over-year [6] - OEM revenue is expected to be approximately$ 9.5 million, representing growth of 6% year-over-year [6] Management Comments - The company expressed satisfaction with its financial performance in Q4 2024, highlighting improved U.S. capital sales and a doubling of generator unit sales compared to the first half of 2024 [4] - There is an increasing demand for treatments addressing loose and lax skin, partly due to significant patient weight loss from GLP-1 drugs, which the company aims to capitalize on [4]